Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics Manufacturing

Core Insights - Ginkgo Bioworks has completed the first milestone of its partnership with Merck, receiving a cash payment of $9 million [1][2][3] - The next phase of the partnership will focus on further improving the biologic manufacturing process [2][3] Company Overview - Ginkgo Bioworks is a leading platform for cell programming, offering end-to-end services across various markets, including pharmaceuticals and biosecurity [4] - The company emphasizes its capabilities in strain engineering, high-throughput screening, and process development, positioning itself as a valuable partner for pharmaceutical companies [3][4]